Holen Sie sich die Stockscreener-App
3.27
2.39%
-0.08
Handel nachbörslich:
3.28
0.010
+0.31%
Lisata Therapeutics Inc Aktie (LSTA) Neueste Nachrichten
Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE) - TradingView
LSTA Forecast — Price Target — Prediction for 2027 - TradingView
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing - GlobeNewswire
Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA) - TradingView
Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lisata Therapeutics Inc (LSTA) Institutional Confidence - TradingKey
Lisata Therapeutics Inc (LSTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lisata Therapeutics Inc (LSTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA) - marketscreener.com
Lisata Therapeutics (LSTA) Rises 2.3% as Stock Tests Key ResistanceHigh Conviction Picks - newsline.com
LSTA Rallies 2.3% to $3.56 as Support Holds Ahead of ResistanceDip Buy Trade - newsline.com
LSTA Q3 2025 Earnings: EPS Beat Exceeds Expectations as Clinical Progress ContinuesQuarterly Financial Update - newsline.com
Lisata shares nearly double on buyout offer: Here are the details - MSN
Kuva Labs Agrees to Acquire Lisata Therapeutics for Four Dollars Per Share - HarianBasis.co
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share - Yahoo Finance
Kuva Labs launches $4/share tender offer to acquire Lisata Therapeutics, plus potential $3/share milestone payments. - Pluang
Lisata Therapeutics (NASDAQ: LSTA) to be acquired for $4.00 cash plus CVRs - Stock Titan
Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA) - Stock Titan
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - GlobeNewswire
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LSTA Q3 2025 Earnings: Narrower Loss Surpasses Estimates as Clinical Progress ContinuesCFO Commentary Report - newsline.com
Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp – Minichart - Minichart
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline - TipRanks
Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17 - TradingView
Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee - Stock Titan
LSTA Q3 2025 Earnings: EPS Surpasses Estimates Despite Lack of Revenue, Stock Edges LowerRetail Earnings Report - newsline.com
LSTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lisata Therapeutics (LSTA) Holds Steady at $3.37 as Key Levels NarrowPCR Spike - newsline.com
Lisata Therapeutics (LSTA) Eases Amid Modest Pullback — Key Support Levels in FocusMoving Average Crossovers - newsline.com
LSTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer - The Globe and Mail
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com UK
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement - Minichart
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss Marks Progress in Clinical-Stage BiotechRevenue Growth Outlook - The Legal Advocate
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics - Kavout
Stocks to Watch: Oculis, Lisata, Healthy Choice Wellness - Moomoo
Lisata Therapeutics Revises Merger Terms, Adds Milestone CVRs - TipRanks
Lisata Therapeutics (LSTA) preliminary tender-offer communication; merger dated March 6, 2026 - Stock Titan
Lisata Therapeuticsamends merger offer price to $4 per share plus CVR - marketscreener.com
Lisata Agrees to $4 Cash Plus Up to $3 CVR in Amended Kuva Tender Offer - TradingView
Lisata (NASDAQ: LSTA) cuts cash to $4, lifts CVR upside to $3 - Stock Titan
LSTALisata Therapeutics Inc Stock Price and Quote - Finviz
LSTA Technical Analysis | Trend, Signals & Chart Patterns | LISATA THERAPEUTICS INC (NASDAQ:LSTA) - ChartMill
LSTA Technical Analysis & Stock Price Forecast - Intellectia AI
Lisata Therapeutics (LSTA) Q3 2025 Earnings: EPS Beat Drives Positive Stock ReactionSubscription Growth Report - The Legal Advocate
Lisata, Mobileye, VF, Canada Goose, F5 Trending With Analysts - TipRanks
Lisata Therapeutics (LSTA) Holds Steady at $3.14 as Range-Bound Trading PersistsLow Volume Node - The Legal Advocate
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):